Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group

Patients with relapsed or refractory (R/R) peripheral T-cell lymphomas (PTCL) have a poor prognosis. Bendamustine (B) and brentuximab-vedotin (Bv) have shown interesting results in this setting. However, little information is available about their efficacy in combination. This multicenter and retros...

Descripción completa

Detalles Bibliográficos
Autores principales: Aubrais, Raphaelle, Bouabdallah, Krimo, Chartier, Loic, Herbaux, Charles, Banos, Anne, Brice, Pauline, Sibon, David, Schiano, Jean Marc, Cluzeau, Thomas, Laribi, Kamel, Le Calloch, Ronan, Bellal, Mathieu, Delapierre, Baptiste, Daguindau, Nicolas, Amorim, Sandy, Agbetiafa, Kossi, Chauchet, Adrien, Besson, Caroline, Durot, Eric, Bonnet, Christophe, Fouillet, Ludovic, Bijou, Fontanet, Tournilhac, Olivier, Gaulard, Philippe, Parrens, Marie-Cécile, Damaj, Gandhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539874/
https://www.ncbi.nlm.nih.gov/pubmed/36477770
http://dx.doi.org/10.1182/bloodadvances.2022008524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539874/
https://www.ncbi.nlm.nih.gov/pubmed/36477770
http://dx.doi.org/10.1182/bloodadvances.2022008524

Ejemplares similares